TABLE 2.

Depression treatment within 365 days after an index depression episode among patients who received a single‐gene CYP2D6 or CYP2C19 test (n = 1795)

Depression treatment characteristic	Received a single‐gene CYP2D6 or CYP2C19 test within 365 days of index depression diagnosis (n = 1795)
Filled an antidepressant, n (%)	1059 (59.0)
Days to earliest fill, mean (SD), median	80.1 (100.6), 29
Filled an antidepressant with a CPIC guideline indicating a potential drug–gene interaction with CYP2D6 or CYP2C19, n (%) a	519 (49.0)
Class of index AD fill, n (%)
SSRIs	567 (53.5)
SNRIs	153 (14.5)
Tricyclic ADs	69 (6.5)
Tetracyclic ADs	45 (4.2)
MAOIs	1 (0.09)
Newer‐generation ADs	224 (21.1)
Timing of antidepressant fill relative to pharmacogenetic test, n (%)
Prior to receipt of the pharmacogenetic test	601 (56.8)
Within 0–14 days after the pharmacogenetic test	140 (13.2)
>14 days after the pharmacogenetic test	318 (30.0)

Abbreviations: AD, antidepressant; CPIC, Clinical Pharmacogenetics Implementation Consortium; MAOI, monoamine oxidase inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

^a Antidepressants with a CPIC guideline indicating a drug–gene interaction with CYP2D6 or CYP2C19 include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, nortriptyline, desipramine, trimipramine, protriptyline, paroxetine, and fluvoxamine, citalopram, escitalopram, sertraline.